Day One Biopharmaceuticals, Inc.
Clinical trials sponsored by Day One Biopharmaceuticals, Inc., explained in plain language.
Day One Biopharmaceuticals, Inc.
DAWN
NASDAQ
Develops targeted therapies for pediatric cancer patients.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug XMT-1660 enters first human tests for Hard-to-Treat cancers Results expected Feb 2027 (estimated)
- New pill may replace chemo for kids with brain tumors Results expected Jun 2027 (estimated) 🚀 Make-or-break